Solid state forms of spiro-oxindole compounds
AssigneeXenon Pharmaceuticals Inc.
InventorsRonen Ben-David, Stephen Bierlmaier, Ralph Curtis Haltiwanger, Alexandr Jegorov, Raeann Ruiyun Wu, Mehran Yazdanian
Life of this patent
Estimating the term…
Abstract
The present invention provides solid state forms of certain spiro-oxindole compounds, such as funapide and the racemic mixture of funapide and its corresponding (R) enantiomer, pharmaceutical compositions comprising the solid state forms and processes for preparing the solid state forms and the pharmaceutical compositions.
Claims11
A crystalline form of funapide, designated as Form A0, characterized by one or more of the following:
- a powder X-ray diffraction pattern having peaks at 10.10°, 10.69°, 20.59°, 22.69° and 33.12° θ±0.2° θ;
- a powder X-ray diffraction pattern substantially as depicted in FIG. 1;
- and any combination of these data.
A method of preparing a crystalline form of funapide designated as Form A0, wherein the method comprises one of the following methods to obtain the crystalline form of funapide designated as Form A0:
- (a) equilibrating funapide at 25±3° C. with a mixture of solvents, filtering the resulting solutions;
- and drying the resulting solids;
- (b) equilibrating funapide at 50° C. with a solvent or mixture of solvents, filtering the resulting solutions and drying the resulting solids;
- (c) dissolving funapide in methyl tert-butyl ether at 22-25° C., cooling the resulting solution to 5° C., filtering the resulting solution and drying the resulting solids;
- (d) dissolving funapide in a solvent or a mixture of solvents at 22-25° C., cooling the resulting solutions to 5° C., maintaining the temperature and allowing the solvent or mixture of solvents to slowly evaporate;
- (e) mixing funapide with a mixture of solvents at 22-25° C., rapidly heating the resulting solutions to 50° C., maintaining the temperature and allowing the mixture of solvents to rapidly evaporate;
- and
- (f) dissolving funapide in a first solvent, in which funapide is soluble, adding a second solvent, in which funapide is insoluble or poorly soluble, and filtering the resulting solutions.
Dependencies are inferred from the claim text.